[{"data":1,"prerenderedAt":26},["ShallowReactive",2],{"project-3a0f6afa69ef5fe200dc0bdb16efc0f1":3},{"_id":4,"slug":4,"title":5,"subtitle":6,"cover":8,"tech_type":9,"indications":10,"official_price":11,"hospital_name":12,"hospital_names":13,"tech_company_name":12,"view_count":14,"favorite_count":15,"is_favorite":16,"approval_no":17,"approval_date":18,"regulatory_level":19,"valid_until":18,"filing_date":20,"intro":21,"detail_desc":22,"target_population":23,"compliance_list":24,"process":25},"3a0f6afa69ef5fe200dc0bdb16efc0f1","肺纤维化的宫血间充质干细胞应用技术",[7],"间质性肺疾病","https://6875-huali-cell-8geyb3yje6a285d1-1419749029.tcb.qcloud.la/assets/cover/1779099630910-010肺纤维化的宫血间充质干细胞治疗技术.jpg","干细胞应用",[7],"14万元/疗程 (3针)","浙江生创精准医疗科技有限公司",[],37,1,false,"乐城第三批获批","","低风险","2025年","\u003Cp>经常规治疗后仍呈进行性纤维化表现的间质性肺疾病(PF-ILD)\u003C/p>\u003Cp>宫血间充质生物医学新技术抑制肺间质纤维化进展、延缓肺功能下降。\u003C/p>\u003Cp>\u003Cb>适应症\u003C/b>:进行性间质性肺疾病 / 肺纤维化\u003Cbr>\u003Cb>技术类型\u003C/b>:生物医学新技术\u003Cbr>\u003Cb>批次\u003C/b>:乐城第三批获批\u003C/p>","宫血间充质干细胞抑制肺间质纤维化进展、延缓肺功能下降。",[],[],[],1779368115444]